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The bioactive sphingolipid sphingosine 1-phosphate (S1P) elicits robust cytoskeletal rearrangement in a large variety of cell systems, mainly
acting through a panel of specific cell surface receptors, named S1P receptors. Recent studies have begun to delineate the molecular mechanisms
involved in the complex process responsible for cytoskeletal rearrangement following S1P ligation to its receptors. Notably, changes of cell shape
and/or motility induced by S1P via cytoskeletal remodelling are functional to the biological action exerted by S1P which appears to be highly cell-
specific. This review focuses on the current knowledge of the regulatory mechanisms of cytoskeleton dynamics elicited by S1P, with special
emphasis on the relationship between cytoskeletal remodelling and the biological effects evoked by the sphingolipid in various cell types.
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Sphingosine 1-phosphate (S1P), is a bioactive sphingolipid
metabolite present in a wide variety of Eukaryotes ranging from
yeasts to Mammals that acts as regulator of key biological
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Studies of the last 15 years have clearly demonstrated that S1P
is generated by sequential action of sphingomyelinase and
ceramidase on sphingomyelin and ceramide respectively,
followed by sphingosine kinase- (SphK-) directed phosphor-
ylation of sphingosine to S1P [1–3]. In agreement with the role
of S1P as autocrine and paracrine regulator of key biological
events, S1P metabolism appears to be strictly regulated. In
Mammals two different gene products, SphK1 and SphK2
catalyze S1P biosynthesis via the ATP-dependent phosphoryla-
tion of sphingosine [1]. SphK1 is a highly regulated enzyme,
controlled by a variety of growth factors, hormones and
cytokines. Multiple mechanisms have been individuated and
proposed as responsible for enzyme translocation from cytosol
to membrane where it becomes functionally active, in favour of
the occurrence of a multifaceted regulation of its enzymatic
activity. Although the knowledge of the molecular properties of
SphK2 and its regulation is still limited, it seems to differ from
SphK1 for subcellular localization and biological role. S1P
breakdown appears also to be quite complex: a specific
lyase catalyzes irreversible S1P degradation to ethanolamine
1-phosphate and palmitaldehyde and specific phosphatases
are responsible for its conversion back to sphingosine. Both
the catabolic pathways of S1P appear to be regulated and
capable of profoundly influencing S1P cellular content and
biological activity [4,5].
It is presently widely accepted that in Mammals S1P exerts
its biological effects through ligation to at least five different
specific receptors, previously known as Edg receptors and now
renamed S1P receptors (S1PRs) [6], whereas in Invertebrates no
sphingolipid-specific receptors have been so far identified in
favour of an exclusively intracellular mechanism of action [2].
Intriguingly, the receptor-dependent biological response elicited
by S1P in a specific cell type appears to be critically dependent
on the typology and the expression levels of receptor subtypes
since some of them are recognized to mediate opposite
biological effects. Besides its action as ligand of S1PRs, in
Mammals S1P, similarly to other bioactive lipids, exerts some of
its effects as intracellular mediator in a receptor-independent
manner [1]. Noticeably, it is widely accepted that the biological
activity of a number of growth factors and cytokines depends at
least in part on the specific stimulation of S1P formation [1].
Moreover, to further support the notion that S1P is an important
regulator of cell physiology, it has been proved that it largely
accounts for the atheroprotective effects exerted by high-density
lipoproteins [7].
In agreement with the fundamental role of cytoskeleton in
the regulation of cell shape and motility, S1P has been
demonstrated to induce profound cytoskeletal rearrangements
in various cell systems, strictly associated to the final biological
response elicited by the sphingolipid.
Before examining the molecular mechanisms by which S1P
can promote cytoskeletal modifications in order to influence
cell shape and motility, a brief overview of the molecular
machinery that comprises cytoskeleton and the involved
regulatory mechanisms are presented in the following section
of the review.2. Cytoskeletal components and their function
Eukaryotic cells have distinct shapes and a high degree of
internal organization. Moreover, they are capable of adapting to
external stimuli by changing their shape, repositioning their
internal organelles and migrating from one place to another. The
cytoskeleton, a complex network of protein filaments localized
in the cytoplasm, has a fundamental role in these processes. The
two most important types of filaments of the cytoskeleton are
microfilaments (7–9 nm of diameter), also referred to as actin
filaments, and microtubules (24 nm of diameter). A third class
of protein filaments with a diameter of 10 nm and for this reason
named intermediate filaments is found in most animal cells.
They are much more stable than microtubules and microfila-
ments and confer mechanical stability to animal cells, providing
support to the plasma membrane in the specific regions where it
interacts with other cells or extracellular matrix, but they do not
have a role in the regulation of cell motility.
Two different mechanisms have been evolved to generate
movement in eukaryotic cells. One is based on the activity of a
special class of enzymes defined molecular motors. These
proteins employ the energy derived from ATP hydrolysis to
move or slide along a microfilament or microtubule. Some
molecular motors transport organelles and/or vesicles along
cytoskeletal fibers, others allow the sliding of fibers one onto
the others. The second mechanism, responsible for many cell
shape changes, implies the assembly and disassembly of
microfilaments and microtubules.
Microfilaments are indeed highly dynamic structures that
result from the polymerization of G-actin monomers [8,9]. They
can be organized as bundles or networks. Parallel bundles of
actin constitute the thin cellular processes named filopodia,
while branched networks of filaments support lamellipodia,
which are membrane protrusions of the plasma membrane
essential for cell motility [10]. Networks of actin filaments
constitute also stress fibers that appear in the cytoplasm of
cultured cells just beneath the plasma membrane in response to
various stimuli. The process of actin polymerization is highly
regulated involving a number of different actin-binding proteins
whose activity is under the control of extracellular cues as well
as phosphoinositides metabolites. Among these are proteins that
induce the nucleation of actin, such as the Arp2/3 complex,
influence the depolymerization of actin, such as cofilin and
actin depolymerizing factor, associate to monomeric actin, such
as profilin, and cap the ends of filaments, such as gelsolin
[9,10]. It is widely accepted that Rho GTPases, fundamental
transducers of a multitude of extracellular signals, drive distinct
dynamic actin-based processes, influencing actin-binding
protein functionality and the activation state of molecular
motors [11].
Similarly to microfilaments, microtubules also represent
highly dynamic structures. They are hollow cylinders
composed of 13 protofilaments of α-tubulin and β-tubulin
dimers in a head to tail fashion. Microtubules are nucleated
and organized by the microtubule-organizing centers such as
centrosomes and basal bodies. They are capable of growing
and shrinking in order to generate force and also allow the
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organization of the mitotic spindle, more recent studies have
clarified an important role of microtubules in cell migration,
being involved in cell polarization [12,13]. Indeed, migrating
cells exhibit a polarized morphology which is accompanied by
an asymmetrical distribution of signalling molecules and the
cytoskeleton, the latter implicating not only microfilaments but
also microtubules.
3. Rho GTPases and their regulation by S1PRs
The Rho family GTPases that belong to the Ras superfamily
of small GTPases, participate to the regulation of the actin
cytoskeleton and other cell adhesion events besides other
fundamental biological processes such as cell cycle progression,
gene expression, vesicle trafficking and cell polarity [11]. Up to
now, 20 genes encoding Rho proteins have been identified that
can be roughly divided into 5 groups: the Rho-like, Rac-like,
Cdc-42-like, Rnd and RhoBTB subfamilies. Other members
(RhoD, Rif, MIRO-1, etc.) have been recently identified; they
display very low homology to the other members of the family
and very little is known about their function [14]. Like other
small GTP-binding proteins, the Rho family GTPases exhibit
high binding affinity for GTP and possess low GTPase and
GTP/GDP exchange activities. The cycling between the GDP-
bound inactive and the GTP-bound active form is regulated by
two classes of regulatory proteins: the guanine nucleotide
exchange factors (GEF) and the GTPase-activating proteins
(GAP). GEF, also known as GDP dissociation stimulators,
promote the binding of GTP, while GAP, stimulating the
intrinsic GTPase activity of the Rho GTPases, induce their
conversion to the GDP-bound state. A number of GEF for
various Rho family GTPases have been identified including Dbl
(specific for Cdc42 and Rho), p115 RhoGEF (specific for Rho),
Tiam (specific for Rac) [14]. Similarly, since the discovery of
p50 RhoGAP, a number of GAP for various Rho family
GTPases have been identified including p190 GAP, Bcr and
Abr. It is interesting to observe that some of the Rho GAP
proteins not only act turning off the Rho signal but also serve as
Rho effectors [15].
Proteins of the Rho-like subfamily (RhoA, RhoB, RhoC) all
display high degree of homology and, when overexpressed,
induce the formation of stress fibers and focal adhesions. The
Rac-like subfamily is involved in the formation of lamellipodia
and membrane ruffles. While Rac1 and RhoG are ubiquitously
expressed, Rac2 and Rac3 expression is restricted to neural and
hematopoietic tissues. The Cdc42-like GTPases all stimulate
the formation of filopodia and actin microspikes, binding to
WASP or N-WASP that are the main effectors in the filopodia
formation [14].
The concept that Rho GTPases act as master regulators of
cytoskeleton assembly in the cell is further strengthened by
their role in the regulation of microtubules, indispensable for
the directional migration of certain cells [16]. It has been
clearly demonstrated that RhoA, but not Rac1 and Cdc42, is
necessary for agonist-induced microtubule reorganization
[17]. Additionally, Cdc42 critically regulates cell polarityduring migration by promoting microtubule-organizing center
reorientation [18].
A number of proteins, targets of the Rho-like subfamily, have
been identified which are relevant for the formation of stress
fibers as a result of myosin-based contractility. These include
Rho-kinase and myosin light chain (MLC) phosphatase that
cooperate in the regulation of the level of MLC phosphorylation
[15]. Several proteins have been identified as targets of Rho-
kinase. Among these, LIM kinase phosphorylates and inhibits
the actin-depolymerizing protein, cofilin, leading to stabiliza-
tion of stress fibers [19]. Another Rho signalling pathway
leading to stress fibers and focal adhesion assembly involves
mDia, the mammalian homolog of D. melanogaster diapha-
nous, that belongs to the Arp2/3-related family of proteins
which can bind profilin, thereby stimulating actin polymeriza-
tion [15,20]. Interestingly, it has been established that mDia is
implicated in the process of microtubule reorganization, critical
for cell polarity [21], supporting the view that the protein plays a
pivotal role in the regulation of cytoskeleton dynamics.
Targets for Rac and/or Cdc42 include p21 activated kinase
(PAK) which is a protein kinase activated by both Rac and
Cdc42, implicated in lamellipodia formation [22] through LIM
kinase [23], filamin activation [24] as well as interaction with
PIX, a GEF for Rac [25]. PAK has also been reported to exert an
indirect role in microtubule stabilization via phosphorylation of
stathmin which is known to destabilize microtubules [26]. Rac
potently induces actin polymerization, activating both phos-
phatidylinositol 5-kinase [27] and WAVE/Scar protein that
stimulates Arp2/3 to nucleate actin [28].
Cell motility implies the extension of one or more lamell-
ipodia from the leading edge of the cell followed by adhesion to
substratum via focal adhesion, the subsequent flow forward of
the cytoplasm and the retraction of the tail into the cell body.
Recent papers highlighted the antagonism between Rho and Rac
signalling pathways as regards the responsiveness to migratory
cues: elevated Rho activity is critical for the inhibition of cell
motility at the rear, while Rac activity is high at the front [29].
Similarly, gradients of phosphatidylinositol 4,5-bisphosphate,
positive regulator of actin polymerization and the actin-binding
protein cofilin, which is inactive at the rear and active at the
front, are observed in migrating cells [14].
Rho GTPases act in signalling pathways downstream of
growth factors and other agents that bind to cell surface
receptors. Among the G-protein coupled receptors, the Edg
family of S1PRs plays an important role in the regulation of the
Rho GTPases. Using baculovirus expression system in Sf9 cells
and GTPγS binding experiments, it has been demonstrated that
S1P1 is primarily coupled to pertussis toxin (PTx)-sensitive Gi/0
proteins, while S1P2 and S1P3 are coupled to Gi as well as Gq
and G12/13 and possibly Gs [30]. S1P4 has later been shown to
transduce signals via Gi/0 and G12/13 [31,32], while S1P5 acts
via Gi and G12 [33]. Characteristics of S1PRs and their relative
downstream signalling pathways have been recently widely
reviewed by Ishii et al. [6].
The ubiquitously expressed and well studied S1P1 receptor
was shown to activate Rac via the βγ subunit of Gi in HEK293
cells, human umbilical vein endothelial cells (HUVEC) and
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induced Rho activation is still questionable since Paik et al.
have demonstrated that in CHO cells both S1P1 and S1P3
mediated stimulation of RhoA [36], while previous studies
excluded S1P1 coupling to Rho stimulation [35,37–40]. These
discrepancies may be due to different expression levels of
endogenous S1PRs in the cell lines employed in overexpression
experiments.
In overexpressing CHO cells S1P2 was shown to activate
Rho through a G12/13-dependent pathway [35,38]. S1P2 also
inhibited Rac activity and prevented cell migration in a G12/13-
dependent manner [35]; moreover, it appears that counter-
acting signals from the Gi and G12/13–Rho pathways positively
or negatively regulate Rac and cell migration [41]. It is
interesting to note that S1P2 is the first G-protein coupled
receptor able to negatively control Rac activity and cell
migration [37].
S1P3 is evolutionary more closely related to S1P1, but its
mediated signalling pathways resemble, with the exception of
Rac activation, that of S1P2 [6]. In CHO-transfected cells and
HUVEC, S1P3 coupling to Gi also resulted in Rac activation
[35,36], while the G13–S1P3 association linked the receptor to
Rho activation [34–36]. Significantly, Rho activation was
unchanged in S1P3-null murine embryonic fibroblasts but was
reduced when S1P2 was ablated, indicating that Rho activation
is mainly mediated by S1P2 [42,43]. To conclude, the threeFig. 1. Schematic diagram of the biological effects dependent on the cubiquitously expressed S1PRs activate the Rho family of
GTPases through overlapping but distinct signalling pathways.
S1P4 and S1P5 are the most recently identified S1PRs; S1P4
expression is restricted to lymphoid and hematopoietic tissues
while S1P5 is detectable in spleen and brain. It has been reported
that S1P4 stimulated Rho activation via the Gi and G12/13
pathway [44]. Moreover, Kohno et al. have recently demon-
strated that S1P promoted cell migration through the activation
of Cdc42 via S1P4 in a PTx-sensitive manner [45]. S1P5 in
oligodendrocytes was reported to induce process retraction via a
Rho-kinase signalling pathway [46].
In the sections below the molecular mechanisms by which
S1P can induce cytoskeletal rearrangements will be considered
in detail together with their involvement in the exerted
biological effects in different organisms and cell types. A
schematic summary is presented in Fig. 1.
4. Invertebrates
Although the present knowledge of the biological role of S1P
in simple Metazoans is still scarce, it has been recently clarified
that the sphingolipid participates to the normal development of
the slime mold D. discoideum. The specific disruption of the
S1P lyase gene results in a mutant strain that produces short
fruiting bodies with a dramatically ticker stalk and reduced
number of spores. Interestingly, in S1P lyase null mutants theytoskeleton rearrangements induced by S1P in different cell types.
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cells were smaller and less elongated than the wild-type
counterparts and lacked filopodia. Moreover, they displayed
an unusual organization of actin with a strong reduction in F-
actin filled pseudopods in the anterior end of the cells [47].
These abnormalities were responsible for the inability of the
mutants to suppress lateral pseudopod formation and for
temporal delay of the response to cAMP-directed chemotaxis
[48]. These effects are likely due to the increase in S1P cellular
content resulting from the disruption of its catabolic pathway,
however the direct involvement of the sphingolipid in the
biological process is still lacking. Another important issue that
will be interesting to address entails the underlying mechanism
of action that must be intracellular given that no homologs of
the S1PRs have been identified in the genome of D.
discoideum.
5. Endothelial cells
Since the initial discovery of S1P as ligand of S1P1 [49],
a G-protein coupled receptor cloned from differentiated
HUVEC, there has been much progress in the unraveling of
the biological action of S1P in endothelium. It is now widely
accepted that S1P elicits strong activation of endothelial cells
resulting in enhanced cell motility, vascular maturation and
angiogenesis [2]. Among the various processes regulated by
S1P, both chemotaxis and vascular barrier integrity are crucially
dependent on cytoskeletal remodelling. Migration of endothelial
cells is critical for correct new vessel formation which takes
place during embryonic development as well as in fetal
vasculogenesis and wound healing. Studies performed in
different laboratories have demonstrated that S1P is a potent
chemoattractant for endothelial cells, capable of profoundly
influencing cell-directed motility at low and physiologically
relevant concentrations [50–52]. Interestingly, S1P resulted to
be a more potent inducer of endothelial cell migration than
known chemoattractants such as vascular endothelial growth
factor or basic fibroblast growth factor [53]. On the basis of the
increased migratory capacity of cells overexpressing S1P1, this
receptor subtype was implicated in the triggering of the
migratory response [50]. In agreement, the attenuation of S1P1
expression by specific antisense oligodeoxyribonucleotides,
inhibited the S1P chemotactic effect in bovine pulmonary artery
endothelial cells [51]. Subsequently S1P1, predominantly
expressed in endothelial cells [34,54], as well S1P3 were
found both involved in the stimulation of chemotactic response
[36,55,56]. More recently, it has been demonstrated by in vivo
RNA interference that S1P1 expression is required in tumor
angiogenesis and its down-regulation may be relevant in anti-
angiogenic therapeutics [57]. The study of the molecular
mechanisms implicated in the chemotactic response to S1P has
highlighted the crucial role of Rho GTPases. Indeed Lee et al.
reported that the formation of stress fibers and cortical actin
structures, which take place in response to the robust
cytoskeletal remodelling elicited by S1P, were inhibited by
cell microinjection with the dominant negative mutant of Rac1,
[34]. C3 exotoxin administration instead strongly reduced stressfibers but not cortical actin formation, supporting the view that
Rac acts upstream of Rho in inducing endothelial cytoskeleton
changes [34]. In the same study, employing antisense oligo-
deoxyribonucleotides, the coupling of S1P1 to cortical actin
assembly and the S1P3-dependent formation of stress fibers was
showed. In accordance with these results, S1P1-null mice
exhibited deficient vascular maturation due to the inability of
newly formed vessels to attract pericytes and vascular smooth
muscle cells [58]; moreover, cells from the S1P1-deficient
mutant showed defective migratory responses to S1P due to their
inability to activate Rac [59]. The crucial role of RhoA GTPase
in the S1P-dependent migration of endothelial cells emerged
also from other studies in which the protein functionality was
abrogated by cell treatment with C3 exotoxin or potentiated by
the enforced expression of the dominant negative RhoA [56,60].
The role of Rho GTPases in S1P-mediated migration has been
further explored. In the study by Ohmori et al. it has been
proposed that membrane ruffling resulting from signals
triggered by S1P1, including Rac activation and assembly of
Crk-associated substrate–Crk complexes, cooperates with the
Rho-dependent responses downstream of S1P3 ligation to
regulate endothelial cell-directed motility [61]. However, the
role of Rho and Rac in the migratory response to S1P is unclear
since when the effect of S1P on Rho and Rac activation was
directly measured utilizing the specific pull-down assay, a strong
activation of Rho and a less marked stimulation of Rac was
detected [36], whereas a weak and delayed activation of RhoA in
respect to Rac emerged from another study [62]. Although
information on the molecular mechanisms that link S1P1 to
monomeric GTPase activation and thus to cell migration in
endothelial cells is, at least in part, still lacking, it is interesting to
note that S1P was found to initiate a specific and singular
signalling pathway that, via the activation of the protein kinase
Akt, was responsible for phosphorylation and transactivation of
S1P1, functionally required for Rac activation, cortical actin
assembly and chemotaxis [63].
A seminal discovery in the biological response elicited by
S1P in endothelial cells is represented by the ability of the
sphingolipid to enhance the endothelial cell barrier integrity
[54]. This process, intimately linked to the cytoskeleton
remodelling, is strictly required for the complete maturation
of new vessels and its dysfunction results in the increase of
vascular permeability which is observed in inflammation, tumor
angiogenesis and atherosclerosis. The protective effect of S1P
on the endothelial barrier integrity was assessed in in vitro
experiments in which transmonolayer electrical resistance was
monitored; S1P1 and, at a lesser extent S1P3, were identified as
responsible for the initiation of the response [54]. Interestingly,
promising results were obtained employing S1P to reduce the
microvascular permeability and inflammation in a murine
model of lipopolysaccharide-induced lung injury [64]. The
molecular mechanisms implicated in the regulation of endothe-
lial cell barrier by S1P have been actively investigated. In
agreement with a fundamental role of the endothelial cytoske-
leton in the regulation of endothelial cell barrier, S1P-dependent
Rac activation appears to be critical for the final biological
response, whereas RhoA, although implicated, it seems to play
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indispensable for the formation of cortical actin filaments.
Cortactin, an actin-binding protein that stimulates actin
polymerization and stabilizes the filamentous actin network,
was shown to be rapidly translocated to cell periphery of S1P-
treated endothelial cells [65,66]. Moreover, S1P challenge
provoked the relocalization of MLC kinase which became
directly associated with cortactin. This protein interaction
resulted functionally important for the protective effect of S1P
on endothelial cell barrier. Cofilin, an actin severing protein that
is inactivated by Rac in the cell periphery via a PAK1- and LIM
kinase-dependent mechanism, is also likely implicated in the
protective action of S1P on vascular barrier integrity [54].
Indeed ablation of PAK1 by overexpression of the dominant
negative mutant significantly reduced cortical actin assembly
induced by S1P [54]. Finally, it has been recently established
that also α-actinin is critical for the regulation of cortical actin
rearrangements and endothelial cell barrier enhancement, being
recruited in caveolin-enriched microdomains by S1P1-directed
activation of Tiam1/Rac1 in a phosphatidylinositol 3-kinase-
dependent manner [67]. Notably, the specific silencing of α-
actinin 1 and 4 isoforms, Tiam1 or S1P1 inhibited S1P-induced
actin cortical rearrangement and S1P-mediated barrier enhance-
ment [67].
The activation of Rho/Rho-kinase pathway was also
discovered to be engaged in the regulation of endothelial
cell barrier function by S1P. Inhibition of Rho-kinase, leading
to increased MLC phosphatase activity resulted in a moderate
decrease in transendothelial monolayer resistance, but did not
alter the formation of the cortical actin ring [54]. Other
important cell players in the maintenance and disruption of
the endothelial barrier are focal adhesion complexes. S1P was
shown to promote tyrosine phosphorylation of focal adhesion
kinase, disassembly of the focal adhesion complex and
redistribution of focal adhesion kinase and paxillin to the
cell periphery, concomitant with the formation of cortical
actin rings [68]. The endothelial barrier function strictly
depends upon adherence of neighboring cells to one another
and to the underlying matrix. S1P induced the Rac-dependent
localization of vascular endothelial cadherin, α-, β-, and γ-
catenin to sites of cell–cell junctions [34,69]. Interestingly,
FTY720-P, a molecule structurally similar to S1P, has been
shown to induce the assembly of adherens junctions in
HUVEC [70]. Recently, the S1P-induced mobilization of
intracellular calcium was found to mediate Rac activation and
adherens junction assembly in human pulmonary arterial
endothelial cells [69] Finally, the S1P-induced microtubule
polymerization was found responsible for the correct
trafficking of N-cadherin to polarized plasma membrane
domains, critical for the adhesion of endothelial cells to mural
cells, necessary for vascular stabilization [71].
6. Smooth muscle
The regulation of smooth muscle tone is important for the
control of blood pressure as well as the correct functioning of
many internal organs. Muscle cell contractility appears to behighly regulated. Increase in MLC phosphorylation can also
occur at constant Ca2+ concentration through inhibition of the
MLC phosphatase [72]. In this regard it has been clearly
established that Rho-kinase, specifically activated by RhoA,
can phosphorylate the MLC phosphatase, inhibiting its activity
[15]. In view of the ability of S1P to activate key signalling
events, including intracellular Ca2+ increase and Rho GTPases
[6], intensive research has been recently carried out to define the
role of the sphingolipid in smooth muscle contractility. Initially
it has been demonstrated that systemic and intrarenal bolus
injections of S1P dose-dependently reduced renal and, to a
smaller extent, mesenteric blood flows in rats, whereas mean
arterial pressure and heart rate were unaffected by the
sphingolipid, indicating a preferential effect of S1P on the
vasculature rather than the heart [73]. Subsequently, results
obtained from various studies, mainly performed in vitro on
different models of arteries, showed contrasting effects on
vasoconstriction and the concentration range of S1P efficacy
[74]. A possible explanation for these apparently conflicting
results can be the occurrence of a highly variable and tissue-
specific distribution of S1PRs, critical for the regulation of
smooth muscle contraction. Indeed in rat cerebral arteries, in
which S1P1, S1P2 and S1P3 are expressed, S1P challenge was
found to increase intracellular Ca2+, activate RhoA, and elicit
contraction whereas in rat aorta that expresses lower levels of
S1P2 and S1P3 compared with cerebral artery, the sphingolipid
produced negligible increase in Ca2+, did not activate RhoA and
did not induce contraction [75]. However, in a different study
where S1P3 was individuated as the major mediator of S1P
vasoconstrictive effect, the sphingolipid was shown to selec-
tively constrict isolated cerebral, but not peripheral arteries,
despite ubiquitous expression of S1P1, S1P2, S1P3 and S1P5
mRNA [76]. S1P2 was instead identified as responsible for
coronary artery smooth muscle contraction elicited by S1P via a
signalling pathway involving Rho-kinase [77]. Also in gastric
smooth muscle cells S1P2-dependent activation of Rho-kinase
resulted to be critical for S1P-mediated contraction [78].
Additionally, S1P was found to induce formation of stress
fibers and contraction of human airway smooth muscle cells
with implications in the pathobiology of asthma [79]. In this
study Rho-kinase pathway appeared to be marginally im-
plicated in the biological response, being involved in the late,
but not acute, phase of S1P-induced contraction; on the
contrary, agonist-induced Ca2+ influx was critical for S1P-
induced contraction.
All in all, these findings demonstrate that S1P signals to the
acto-myosin contractile apparatus to regulate smooth muscle
contraction mainly via S1P2 and S1P3 which act through Rho-
kinase activation and Ca2+ mobilization; however, their specific
role may differ in various muscle types in view of their possible
specific differential coupling to downstream pathways. Addi-
tional investigation is therefore required to fully characterize the
molecular machinery involved in the S1P-mediated regulation
of smooth muscle.
The molecular effects exerted by S1P on smooth muscle
cytoskeleton are also responsible for the regulation of cell
motility. Indeed, a pioneering study on the biological activity
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S1P interfered with the dynamics of actin filament assembly and
disassembly stimulated by platelet-derived growth factor
(PDGF), inhibiting the growth factor-induced chemotaxis and
formation of lamellipodia in arterial smooth muscle cells [80].
The peculiar anti-chemotactic effect of S1P in smooth muscle
cells, opposite to the chemotactic activity exerted by the
sphingolipid in endothelial cells, was successively confirmed in
other studies [81,82]. The investigation of the molecular
mechanisms involved in the S1P-dependent inhibition of
directed cell motility clarified a crucial role for the inhibition
of Rac, whose activity is essential for lamellipodia formation.
Moreover, in vascular smooth muscle cells the inhibition of Rac
activation and cell chemotaxis by S1P was ascribed to the
preferential signalling of the sphingolipid via S1P2, since in
overexpression experiments S1P2 was found to reduce Rac
activation [81]. In agreement, Kluk and Hla showed that
inhibitory or stimulatory action of S1P on smooth muscle cell
chemotaxis depends on the level of S1P2 [83]. More recently,
S1P was shown to inhibit PDGF-induced Rac activation and
chemotaxis also in airway smooth muscle; S1P2 appeared to be
implicated in the response, being S1P action suppressed by the
S1P2 antagonist JTE-013 [84]. Interestingly, S1P-induced
cytoskeletal remodelling was found implicated in the regulation
of transcriptional activity of smooth muscle cells: the expression
of connective tissue growth factor, encoded by an immediate
early gene, was promoted by S1P through a RhoA pathway
which was dependent on increased polymerization of actin
filaments, resulting in decreased G- to F-actin ratio [85].
7. Skeletal muscle cells
C2C12 myoblasts, which are murine satellite cells largely
employed to investigate skeletal muscle cell biology, bear on
their surface at least three different S1PRs, S1P1, S1P2 and S1P3
[86]. In these cells S1P was found to induce actin cytoskeleton
reorganization, as showed by the appreciable redistribution of
G-actin polymers in myoblasts loaded with fluorescent G-actin
monomers [87]. Moreover, myoblast challenge with S1P
stimulated cell contraction via a mechanism dependent on
Rho/Rho-kinase activation pathway whereas the agonist-
induced rise in intracellular Ca2+ resulted to be unnecessary
for the contractile response [88]. The biological meaning of the
Rho-dependent S1P-induced myoblast contraction has not been
so far investigated but it is tempting to speculate that it
represents a mean by which the bioactive sphingolipid regulates
skeletal muscle differentiation in view of the well-known role of
Rho family proteins as regulators of skeletal myogenesis [89].
This hypothesis is further supported by the recent finding that
indeed S1P acts as strong inducer of the myogenic differentia-
tion program in these cells, via a p38 MAPK-dependent
signalling pathway [90]. The cytoskeletal response elicited by
S1P in C2C12 cells was recently further explored. The bioactive
sphingolipid was found to induce the appearance of actin stress
fibers and focal adhesions. The rearrangement of actin
cytoskeleton required the ligation of S1P to its specific
membrane receptors since the intracellular delivery of thesphingolipid by microinjection was unable to modify the
cytoskeletal actin assembly [91]. As regards the signalling
pathways implicated in the S1P-induced stress fiber formation,
RNA interference experiments support the engagement of S1P3
(Meacci, E. et al. unpublished data); moreover, the Rho/Rho-
kinase as well as the phospholipase D pathways resulted to be
involved whereas ERK1/2 and p38 MAPK were not required
for the S1P response [91]. Interestingly, in the same report, by
whole-cell patch-clamp studies the formation of stress fibers
induced by S1P was revealed to be associated with increased
ion currents and conductance through stretch-activated channels
permeable to Ca2+, suggesting the occurrence of a role for
organized actin in the regulation of channel sensitivity, which
can be relevant from the physiological point of view linking the
S1P-induced cytoskeletal rearrangement to the regulation of
intracellular Ca2+.
Interestingly, it has been observed that RhoA activation
elicited by S1P in C2C12 myoblasts, appears also to be critical
for the inhibition of directional cell motility induced by the
sphingolipid [92]. Indeed, S1P was identified as powerful anti-
chemotactic agent in these cells, capable of fully abrogating
the migratory response to insulin-like growth factor-I,
essentially via S1P2-mediated RhoA activation. This conclu-
sion stems from the finding that the anti-migratory action of
S1P was significantly reduced by enforced expression of the
dominant negative mutant of RhoA but unaffected by
expression of either the constitutively active or the dominant
negative mutant of Rac1. This finding is reminiscent of what
individuated in glioblastoma cells where S1P2 was discovered
to regulate RhoA without exerting the concomitant inhibition
of Rac and demonstrated to be critical for the inhibition of
tumor cell migration [93]. The anti-chemotactic effect exerted
by S1P in myoblasts was unaffected by cell treatment with
Y27632, specific inhibitor of Rho-kinase, excluding the
involvement of this pathway in the mechanism of S1P action
[92]. Although in C2C12 cells RhoA activation appears to be
upstream of a number of different biological responses, some
of them, including cell contraction and stress fiber formation,
depend on RhoA-directed Rho-kinase activation whereas
others, such as the inhibition of cell migration, implicate
RhoA targets different from Rho-kinase which have not been
so far identified.
8. Immune cells
S1P and its specific receptor S1P1 are recognized to
constitute a system that controls thymocyte emigration into
blood and the recirculation and tissue redistribution of T and B
cells, exerting direct chemotactic effects. This topic has been
recently reviewed [94,95]. Despite the continuing investiga-
tion since the initial discovery that S1P modulates the
migratory response of naïve lymphocytes [96,97], details
concerning the molecular mechanisms implicated in this
important physiological response are still lacking. However,
a critical role in the control of lymphocyte cytoskeleton
dynamics by S1P can be predicted, also in view of a recent
study in which lymphocytes were treated with FTY720. This
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phosphorylation, acts in these cells by binding to S1P1, was
shown to provoke an appreciable up-regulation of proteins
associated with cytoskeleton such as PTEN, Rho and Crk-
associated substrate [98]. Moreover, recent studies have
clarified that S1P regulates the motility of cell types that
play a primary role in adaptive immune response, other than
lymphocytes. Actin polymerization and chemotaxis appear to
be stimulated by the bioactive lipid in human immature
dendritic cells, which are specialized antigen-presenting cells,
whereas the biological response to S1P is lost in dendritic cells
matured with lipopolysaccharide [99]. These findings are in
contrast with a recent study in which only mature murine
dendritic cells were found capable of migrating towards S1P,
in agreement with the appreciable up-regulation of S1P1 and
S1P3 in maturing cells [100]. The employment of several
toxins to specifically inhibit the functioning of Rho family
proteins revealed the dependency of dendritic cell migration
on the integrity of signal transmission by small GTPases; in
particular the simultaneous activity of Rac/Cdc42 and RhoA
appeared to be required for the biological response to the
sphingolipid [100]. At present it is not clear whether the
discrepancy between human and murine dendritic cells relies
on inborn divergence between the two animal species or is
rather due to the different sources employed for progenitors of
dendritic cells (blood in human vs. bone marrow in mouse).
The motility of natural killer cells, which are anti-tumor and
anti-viral effector cells, is also robustly stimulated by S1P,
with a phosphatidylinositol 3-kinase-dependent mechanism
[101]. Interestingly, local in vivo S1P administration promoted
inflammation and appreciable recruitment of eosinophils;
moreover, S1P stimulated in vitro migration of human
eosinophils, also by up-regulating the chemokine receptor
CCR3 [102]. Finally, S1P appears also to regulate the motility
of mast cells, which play a central role in inflammatory and
immediate-type allergic reactions. According to Yokoo et al.,
the challenge of RBL-2H3 mast cells with S1P inhibited, via
S1P2, the spontaneous motility as well as the fibronectin-
induced migration [103]. However, in the same cell line as
well as in bone marrow-derived mast cells in a different study
S1P1 was found implicated in the chemotactic response to S1P
[104]. Importantly, SphK-mediated formation of S1P and
subsequent S1P1 engagement appeared to be implicated in the
migration of mast cells toward antigen [104].
9. Neuronal cells
In neuronal cells actin cytoskeleton dynamics is essential for
directed neurite outgrowth and the generation/rearrangement of
synaptic connectivity. An early study in N1E-115 neuronal cells
showed that S1P induced neurite retraction and cell rounding
through Rho-dependent contraction of the actin cytoskeleton
[39]. Accordingly, addition of S1P to PC12 cells transiently
expressing S1P2 caused cell rounding [40]. A recent compre-
hensive study in PC12 cells clearly showed that the nerve
growth factor- (NGF-) directed neurite extension required
stimulation of SphK activity and transactivation of S1PRs[105]. In particular, administration of NGF rapidly down-
regulated S1P2 but not S1P1, and ectopic expression of S1P1
potentiated the effect of NGF on neurite formation, whereas
overexpression of S1P2 strongly inhibited the NGF effect. In the
same study it was observed that overexpression of S1P1 or S1P2
enhanced or reduced, respectively, NGF-induced Rac activa-
tion, confirming the crucial role of Rac activity modulation in
the control of neurite outgrowth.
10. Tumor cells
Cell motility plays a pivotal role in patho-physiological
processes important for malignant progression such as
metastasis. In this regard attention has been paid to examine
the effect of S1P on migration of various tumor cells. A
seminal early study described the inhibitory action of S1P on
migration of mouse melanoma cells [106]. The sphingolipid
was successively showed to act by inhibiting actin nucleation
and pseudopodia formation [107] via interaction with a cell
surface receptor [108]. Subsequently, it was demonstrated that
S1P2 is the sole S1PR expressed in B16 melanoma cells,
crucially implicated in the negative regulation of cell motility
and invasion, being S1P effect prevented by cell treatment with
the specific S1P2 antagonist JTE013 [109]. Rho proteins were
also found to be significantly regulated by S1P via S1P2: Rac
resulted to be inhibited whereas Rho was stimulated. Inhibition
of Rho by C3 exotoxin abolished the anti-migratory response,
whilst attenuation of Rac functionality by expression of the
dominant negative mutant mimicked S1P inhibition of
migration [109]. In human breast cancer cells S1P, at high
micromolar concentration, was described to reduce chemotactic
motility; however, differently from the majority of S1P effects,
in this case the sphingolipid was reported to act independently
from binding to its specific cell surface receptors, being its
action mimicked by caged S1P only upon UV irradiation [110].
The molecular mechanism by which S1P inhibits motility of
breast cancer cells was shown to involve autophosphorylation
of focal adhesion kinase [111]. The role of S1P on tumor cell
migration was investigated also in glioblastoma cells. S1P was
reported to stimulate cell motility and invasiveness in a human
glioblastoma cell line [112], whilst in C6 glioma cells S1P at
physiologically active concentration inhibited cell migration
[113]. Notably, in a recent study in which S1PR expression
level was comprehensively evaluated in several human
glioblastoma cell lines concomitantly with S1P effect on cell
motility, it was clearly established that S1P differentially
affected glioblastoma cell motility, inhibiting the process when
S1P dominantly signals via S1P2 [93]. Interestingly, the S1P-
mediated inhibition of cell motility was accompanied by a
pronounced formation of stress fibers. The mechanism by
which S1P2 drives inhibition of cell motility in glioblastoma
cells appears to be different from that proposed by Arikawa et
al. in melanoma cells [109] and Ryu et al. in smooth muscle
cells [81], since RhoA/Rho-kinase activation but not inhibition
of Rac activity was implicated. Although this issue was not
specifically addressed in glioblastoma cells, it is conceivable to
hypothesize the involvement of the protein phosphatase PTEN
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response elicited by S1P2 [114].
11. Conclusion
Within the past few years there has been much progress in
understanding the molecular mechanisms by which S1P
regulates cytoskeleton dynamics and the implications of the
sphingolipid-mediated cytoskeletal rearrangements in the
evoked biological response. More work is however required
to delineate a comprehensive picture, also in view of the high
degree of cell specificity of both S1P signalling and regulatory
mechanisms of cytoskeleton dynamics. With the aid of novel
techniques such as RNA interference and fluorescence
resonance energy transfer, the identity and the subcellular
localization of the critical molecular components of S1P-
induced cytoskeletal remodelling will be likely individuated in
the near future. The accomplishment of these studies will not
only contribute to the comprehension of the molecular
machinery that regulates cell shape and motility but, con-
ceivably, will highlight new pharmacological targets critical for
the therapy of a number of disease states in which the
cytoskeleton-dependent S1P response is altered.
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